These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35018785)

  • 1. Risk of second primary malignancies associated with radiotherapy in prostate cancer patients: competing risk analysis.
    Wu Y; Li Y; Han C; Chong Y; Kang K; Liu Z; Zhang F
    Future Oncol; 2022 Feb; 18(4):445-455. PubMed ID: 35018785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies.
    Krasnow RE; Rodríguez D; Nagle RT; Mossanen M; Kibel AS; Chang SL
    Urol Oncol; 2018 Nov; 36(11):500.e11-500.e19. PubMed ID: 30249519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between radiation therapy for primary endometrial cancer and risk of second primary malignancies: a retrospective cohort study.
    Wang Y; Cai Y
    Sci Rep; 2024 Oct; 14(1):24623. PubMed ID: 39427001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Risk of Second Primary Malignancies in Patients With Lung Neuroendocrine Tumors: A Population-Based Study on SEER Database.
    Bu X; Wang X; Wei L; Liu J; Chen M
    Curr Probl Cancer; 2020 Dec; 44(6):100613. PubMed ID: 32563531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The characteristics of bladder cancer after radiotherapy for prostate cancer.
    Abern MR; Dude AM; Tsivian M; Coogan CL
    Urol Oncol; 2013 Nov; 31(8):1628-34. PubMed ID: 22575239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the risk of second primary malignancies in laryngeal cancer survivors: insights from the SEER database.
    Afify AY; Ashry MH
    Eur Arch Otorhinolaryngol; 2024 Aug; 281(8):4409-4417. PubMed ID: 38775833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
    Moschini M; Zaffuto E; Karakiewicz PI; Andrea DD; Foerster B; Abufaraj M; Soria F; Mattei A; Montorsi F; Briganti A; Shariat SF
    Eur Urol; 2019 Feb; 75(2):319-328. PubMed ID: 30293908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignancies diagnosed before and after anal squamous cell carcinomas: A SEER registry analysis.
    Jani KS; Lu SE; Murphy JD; Romesser PB; Jethwa KR; Li D; Chundury A; Wu AJ; Hathout L; Hallemeier CL; Jabbour SK
    Cancer Med; 2021 Jun; 10(11):3575-3583. PubMed ID: 33960690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A population-based study of subsequent primary malignancies after endometrial cancer: genetic, environmental, and treatment-related associations.
    Brown AP; Neeley ES; Werner T; Soisson AP; Burt RW; Gaffney DK
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):127-35. PubMed ID: 19910129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of colorectal cancer and prostate cancer and impact of radiation therapy.
    Huo D; Hetzel JT; Roy H; Rubin DT
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):1979-85. PubMed ID: 19531678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of second cancers according to radiation therapy technique and modality in prostate cancer survivors.
    Berrington de Gonzalez A; Wong J; Kleinerman R; Kim C; Morton L; Bekelman JE
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):295-302. PubMed ID: 25636756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and risk outcomes of second primary malignancy of patients with post-operative colorectal cancer.
    Yang J; Wu F; An H; Gan H
    Int J Colorectal Dis; 2023 Mar; 38(1):88. PubMed ID: 36995483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery.
    Brenner DJ; Curtis RE; Hall EJ; Ron E
    Cancer; 2000 Jan; 88(2):398-406. PubMed ID: 10640974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks for noncutaneous second primary malignancy in cutaneous malignant melanoma survivors: an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) program.
    Vakharia PP; Kelm RC; Orrell KA; Patel KR; Singam V; Ali Y; Rastogi S; Yousif R; Rangel SM; West DP; Nardone B
    Int J Dermatol; 2020 Apr; 59(4):463-468. PubMed ID: 31971260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between radiotherapy and risk of second primary malignancies in patients with resectable lung cancer: a population-based study.
    Zhou B; Zang R; Song P; Zhang M; Bie F; Bai G; Li Y; Huai Q; Han Y; Gao S
    J Transl Med; 2023 Jan; 21(1):10. PubMed ID: 36624443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of mesothelioma following external beam radiotherapy for prostate cancer: a cohort analysis of SEER database.
    Farioli A; Violante FS; Mattioli S; Curti S; Kriebel D
    Cancer Causes Control; 2013 Aug; 24(8):1535-45. PubMed ID: 23702885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Radiotherapy on the Incidence of Secondary Malignancies: A Pan-Cancer Study in the US SEER Cancer Registries.
    Li W; Xiao H; Xu X; Zhang Y
    Curr Oncol; 2021 Jan; 28(1):301-316. PubMed ID: 33435562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study.
    Giri S; Bhatt VR; Verma V; Pathak R; Bociek RG; Vose JM; Armitage JO
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):569-574. PubMed ID: 28709798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Incidence and Survival of Secondary Malignancies after External Beam Radiotherapy for Prostate Cancer in the SEER Database.
    Chin JL
    Eur Urol; 2024 Oct; 86(4):376. PubMed ID: 38744634
    [No Abstract]   [Full Text] [Related]  

  • 20. Estimating the risk of developing secondary hematologic malignancies in patients with T1/T2 prostate cancer undergoing diverse treatment modalities: A large population-based study.
    Mo X; Zhou M; Yan H; Chen X; Wang Y
    Cancer Med; 2021 Aug; 10(15):5338-5346. PubMed ID: 34189859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.